Towards Multidrug Adaptive Therapy

Driving tumor evolution into periodic, repeatable treatment cycles provides a path forward for multidrug adaptive therapy. A new ecologically inspired paradigm in cancer treatment known as “adaptive therapy” capitalizes on competitive interactions between drug-sensitive and drug-resistant subclones. The goal of adaptive therapy is to maintain a controllable stable tumor burden by allowing a significant population of treatment-sensitive cells to survive. These, in turn, suppress proliferation of the less-fit resistant populations. However, there remain several open challenges in designing adaptive therapies, particularly in extending these therapeutic concepts to multiple treatments. We present a cancer treatment case study (metastatic castrate-resistant prostate cancer) as a point of departure to illustrate three novel concepts to aid the design of multidrug adaptive therapies. First, frequency-dependent “cycles” of tumor evolution can trap tumor evolution in a periodic, controllable loop. Second, the availability and selection of treatments may limit the evolutionary “absorbing region” reachable by the tumor. Third, the velocity of evolution significantly influences the optimal timing of drug sequences. These three conceptual advances provide a path forward for multidrug adaptive therapy. Significance: Driving tumor evolution into periodic, repeatable treatment cycles provides a path forward for multidrug adaptive therapy.

[1]  Camille Stephan-Otto Attolini,et al.  Evolutionary Theory of Cancer , 2009, Annals of the New York Academy of Sciences.

[2]  Ville Mustonen,et al.  Predicting evolution , 2017, Nature Ecology &Evolution.

[3]  A. Deutsch,et al.  Studying the emergence of invasiveness in tumours using game theory , 2008, 0810.4724.

[4]  David Basanta,et al.  Fibroblasts and Alectinib switch the evolutionary games played by non-small cell lung cancer , 2017, Nature Ecology & Evolution.

[5]  P. Majumder,et al.  Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition , 2015, Nature Communications.

[6]  K. Pienta,et al.  Evolution of cooperation among tumor cells , 2006, Proceedings of the National Academy of Sciences.

[7]  T. Vincent,et al.  Lessons from applied ecology: cancer control using an evolutionary double bind. , 2009, Cancer research.

[8]  A. Jackson,et al.  The mutation rate and cancer. , 1998, Genetics.

[9]  J. Fletcher Evolutionary Game Theory, Natural Selection, and Darwinian Dynamics , 2006, Journal of Mammalian Evolution.

[10]  J. Salk Clonal evolution in cancer , 2010 .

[11]  S. Schuster,et al.  Evolutionary game theory: cells as players. , 2014, Molecular bioSystems.

[12]  Robert A Gatenby,et al.  Application of Evolutionary Principles to Cancer Therapy. , 2015, Cancer research.

[13]  David Basanta,et al.  Homeostasis Back and Forth: An Eco-Evolutionary Perspective of Cancer , 2016, bioRxiv.

[14]  M. Perry The Chemotherapy Source Book , 1992, Annals of Internal Medicine.

[15]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[16]  Robert Axelrod,et al.  Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. , 2008, Translational oncology.

[17]  Robert A. Gatenby,et al.  Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer. , 2018, Journal of theoretical biology.

[18]  M. Gerlinger,et al.  How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine , 2010, British Journal of Cancer.

[19]  Michael F. Brown Forum: On Resisting Resistance , 1996 .

[20]  John Vontas,et al.  Country-level operational implementation of the Global Plan for Insecticide Resistance Management , 2013, Proceedings of the National Academy of Sciences.

[21]  Folco Giomi,et al.  Nothing in experimental biology makes sense except in the light of ecology and evolution – correspondence on J. Exp. Biol. 216, 2771-2782 , 2013, Journal of Experimental Biology.

[22]  Krishnendu Chatterjee,et al.  Evolutionary dynamics of cancer in response to targeted combination therapy , 2013, eLife.

[23]  R. Gadagkar Nothing in Biology Makes Sense Except in the Light of Evolution , 2005 .

[24]  N. Socci,et al.  Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.

[25]  Carlo C. Maley,et al.  Overlooking Evolution: A Systematic Analysis of Cancer Relapse and Therapeutic Resistance Research , 2011, PloS one.

[26]  C. Sima,et al.  Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[28]  Robert Noble,et al.  Spatial competition constrains resistance to targeted cancer therapy , 2017, Nature Communications.

[29]  A. Deutsch,et al.  Evolutionary game theory elucidates the role of glycolysis in glioma progression and invasion , 2008, Cell proliferation.

[30]  B. Frieden,et al.  Adaptive therapy. , 2009, Cancer research.

[31]  Nick Jagiella,et al.  Estimating Dose Painting Effects in Radiotherapy: A Mathematical Model , 2014, PloS one.

[32]  Jeffrey West,et al.  The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory. , 2019, JCO clinical cancer informatics.

[33]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[34]  Robert A. Gatenby,et al.  Optimizing Cancer Treatment Using Game Theory: A Review , 2019, JAMA oncology.

[35]  Rebecca Ryan,et al.  Analysis of after-action reporting by deployed nurses. , 2008, Military medicine.

[36]  A. Liebman,et al.  Systematic Reviews: Synthesis of Best Evidence for Health Care Decisions , 1998, Annals of Internal Medicine.

[37]  Joel s. Brown,et al.  Classifying the evolutionary and ecological features of neoplasms , 2017, Nature Reviews Cancer.

[38]  Alexander Lorz,et al.  Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation. , 2015, Cancer research.

[39]  Robert A Gatenby,et al.  Evolutionary Strategy for Systemic Therapy of Metastatic Breast Cancer: Balancing Response with Suppression of Resistance , 2014, Women's health.

[40]  Robert A. Gatenby,et al.  Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy , 2019, Clinical Cancer Research.

[41]  Franziska Michor,et al.  Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies , 2009, PLoS Comput. Biol..

[42]  David Basanta,et al.  Exploiting evolution to treat drug resistance: combination therapy and the double bind. , 2011, Molecular pharmaceutics.

[43]  Joel s. Brown,et al.  Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer , 2017, Nature Communications.

[44]  Robert J Woods,et al.  How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient , 2017, PLoS biology.

[45]  B. Foth,et al.  Resisting resistance , 2012, Nature Reviews Microbiology.

[46]  Joel s. Brown,et al.  Why Darwin would have loved evolutionary game theory , 2016, Proceedings of the Royal Society B: Biological Sciences.

[47]  Frank Thuijsman,et al.  Spatial vs. non-spatial eco-evolutionary dynamics in a tumor growth model. , 2017, Journal of theoretical biology.

[48]  David Basanta,et al.  Exploiting ecological principles to better understand cancer progression and treatment , 2013, Interface Focus.

[49]  Jeffrey West,et al.  Capitalizing on Competition: An Evolutionary Model of Competitive Release in Metastatic Castrate Resistant Prostate Cancer Treatment , 2017, bioRxiv.

[50]  P K Newton,et al.  Nonlinear adaptive control of competitive release and chemotherapeutic resistance. , 2019, Physical review. E.

[51]  Robert A Gatenby,et al.  Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies , 2017, bioRxiv.

[52]  Christa-Marie Singleton,et al.  An analysis of root cause identification and continuous quality improvement in public health H1N1 after-action reports. , 2014, Journal of public health management and practice : JPHMP.

[53]  Ville Mustonen,et al.  The value of monitoring to control evolving populations , 2014, Proceedings of the National Academy of Sciences.

[54]  T. Dobzhansky Nothing in Biology Makes Sense Except in the Light of Evolution , 1973 .

[55]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .

[56]  Janet Hemingway,et al.  Implementation of the global plan for insecticide resistance management in malaria vectors: progress, challenges and the way forward , 2015, Malaria Journal.

[57]  David Liao,et al.  Conceptualizing a tool to optimize therapy based on dynamic heterogeneity , 2012, Physical biology.

[58]  Chen-Hsiang Yeang,et al.  Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer , 2012, Proceedings of the National Academy of Sciences.

[59]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.

[60]  Yang Kuang,et al.  Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method. , 2014, Cancer research.

[61]  R. Gillies,et al.  Evolutionary dynamics of carcinogenesis and why targeted therapy does not work , 2012, Nature Reviews Cancer.

[62]  Stephanie Forrest,et al.  Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.